SLC5A2 and type 2 diabetes mellitus: The first is ipragliflozin L-proline, a 1:1 cocrystal of the selective SGLT2 inhibitor ipragliflozin with L-proline, which received approval in Japan in 2014 for the treatment of Type 2 diabetes (Suglat® Tablet; Astellas) [10,11]; to the best of our knowledge, it is not yet available in the USA or European countries.